生物技术公司Savara在第3阶段试验具有孤儿药物地位的罕见肺病药物。 Biotech company Savara in Phase 3 trials for rare lung disorder drug with Orphan Drug status.
Savara公司是一家临床阶段生物技术公司,为一种罕见的肺病(APAP)研制molgramostim,目前正在第3阶段试验中。 Savara, Inc. is a clinical-stage biotech company developing molgramostim for a rare lung disorder, aPAP, currently in Phase 3 trials. 它具有孤儿药物的地位和巨大的增长潜力。 It has Orphan Drug status and significant growth potential. 文章强调了有利于小盘股和低价股的趋势，包括 Applied Digital Corporation、Ironwood Pharmaceuticals、Autolus Therapeutics 和 Indie Semiconductor，这些股票都被视为 2025 年的潜在倍增股，对风险承受能力强的投资者具有吸引力。 The article highlights a trend favoring small-cap and penny stocks, including Applied Digital Corporation, Ironwood Pharmaceuticals, Autolus Therapeutics, and Indie Semiconductor, all viewed as potential multibaggers for 2025, appealing to risk-tolerant investors.